Distinct roles of hepatocyte- and myeloid cell-derived IL-1 receptor antagonist during endotoxemia and sterile inflammation in mice

Journal of Immunology

Volumn 185, Issue 4, 2010, Pages 2516-2524

  Lamacchia, Céline ^a,b   Palmer, Gaby ^a,b   Bischoff, Loraine ^c   Rodriguez, Emiliana ^a,b   Talabot Ayer, Dominique ^a,b   Gabay, Cem ^a,b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; ENDOTOXIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CELL FUNCTION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENDOTOXEMIA; FEMALE; INFLAMMATION; LIVER CELL; MALE; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; SEPTIC SHOCK; ANIMAL; BLOOD; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; IMMUNOHISTOCHEMISTRY; LIVER; LUNG; METABOLISM; MOUSE MUTANT; PATHOPHYSIOLOGY; PHYSIOLOGY; SPLEEN; SURVIVAL;

ACUTE-PHASE PROTEINS; ANIMALS; ENDOTOXEMIA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATOCYTES; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; LIPOPOLYSACCHARIDES; LIVER; LUNG; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID CELLS; SPLEEN; SURVIVAL ANALYSIS;

EID: 77956931737     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1000872     Document Type: Article

References (40)

1. Gabay, C., C. Lamacchia, and G. Palmer. 2010. IL-1 pathways in inflammation and human diseases. Nat. Rev. Rheumatol. 6: 232-241.doi:10.1038/ nrrheum.2010.4.
2. Aksentijevich, I., S. L. Masters, P. J. Ferguson, P. Dancey, J. Frenkel, A. van Royen-Kerkhoff, R. Laxer, U. Tedgård, E. W. Cowen, T. H. Pham, et al. 2009. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N. Engl. J. Med. 360: 2426-2437.
3. Reddy, S., S. Jia, R. Geoffrey, R. Lorier, M. Suchi, U. Broeckel, M. J. Hessner, and J. Verbsky. 2009. An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N. Engl. J. Med. 360: 2438-2444.
4. Arend, W. P., G. Palmer, and C. Gabay. 2008. IL-1, IL-18, and IL-33 families of cytokines. Immunol. Rev. 223: 20-38.
5. Pétrilli, V., and F. Martinon. 2007. The inflammasome, autoinflammatory diseases, and gout. Joint Bone Spine 74: 571-576.
6. Hirsch, E., V. M. Irikura, S. M. Paul, and D. Hirsh. 1996. Functions of interleukin 1 receptor antagonist in gene knockout and overproducing mice. Proc. Natl. Acad. Sci. USA 93: 11008-11013.
7. Horai, R., S. Saijo, H. Tanioka, S. Nakae, K. Sudo, A. Okahara, T. Ikuse, M. Asano, and Y. Iwakura. 2000. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J. Exp. Med. 191: 313-320.
8. Ma, Y., S. Thornton, G. P. Boivin, D. Hirsh, R. Hirsch, and E. Hirsch. 1998. Altered susceptibility to collagen-induced arthritis in transgenic mice with aberrant expression of interleukin-1 receptor antagonist. Arthritis Rheum. 41: 1798-1805.
9. Palmer, G., D. Talabot-Ayer, G. Kaya, and C. Gabay. 2007. Type I IL-1 receptor mediates IL-1 and intracellular IL-1 receptor antagonist effects in skin inflammation. J. Invest. Dermatol. 127: 1938-1946.
10. Nicklin, M. J., D. E. Hughes, J. L. Barton, J. M. Ure, and G. W. Duff. 2000. Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. J. Exp. Med. 191: 303-312.
11. Merhi-Soussi, F., B. R. Kwak, D. Magne, C. Chadjichristos, M. Berti, G. Pelli, R. W. James, F. Mach, and C. Gabay. 2005. Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. Cardiovasc. Res. 66: 583-593.
12. Dinarello, C. A. 1996. Biologic basis for interleukin-1 in disease. Blood 87: 2095-2147.
13. Cannon, J. G., R. G. Tompkins, J. A. Gelfand, H. R. Michie, G. G. Stanford, J. W. van der Meer, S. Endres, G. Lonnemann, J. Corsetti, B. Chernow, et al. 1990. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J. Infect. Dis. 161: 79-84.
14. Casey, L. C., R. A. Balk, and R. C. Bone. 1993. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann. Intern. Med. 119: 771-778.
15. Girardin, E., G. E. Grau, J. M. Dayer, P. Roux-Lombard, and P. H. Lambert. 1988. Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N. Engl. J. Med. 319: 397-400.
16. Irikura, V. M., M. Lagraoui, and D. Hirsh. 2002. The epistatic interrelationships of IL-1, IL-1 receptor antagonist, and the type I IL-1 receptor. J. Immunol. 169: 393-398.
17. Li, P., H. Allen, S. Banerjee, S. Franklin, L. Herzog, C. Johnston, J. McDowell, M. Paskind, L. Rodman, J. Salfeld, et al. 1995. Mice deficient in IL-1 beta-converting enzyme are defective in production of mature IL-1 beta and resistant to endotoxic shock. Cell 80: 401-411.
18. Ohlsson, K., P. Björk, M. Bergenfeldt, R. Hageman, and R. C. Thompson. 1990. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 348: 550-552.
19. Alexander, H. R., G. M. Doherty, C. M. Buresh, D. J. Venzon, and J. A. Norton. 1991. A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in mice. J. Exp. Med. 173: 1029-1032.
20. Wakabayashi, G., J. A. Gelfand, J. F. Burke, R. C. Thompson, and C. A. Dinarello. 1991. A specific receptor antagonist for interleukin 1 prevents Escherichia coli-induced shock in rabbits. FASEB J. 5: 338-343.
21. Fisher, C. J., Jr., J. F. Dhainaut, S. M. Opal, J. P. Pribble, R. A. Balk, G. J. Slotman, T. J. Iberti, E. C. Rackow, M. J. Shapiro, R. L. Greenman, et al. 1994. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 271: 1836-1843.
22. Fisher, C. J., Jr., G. J. Slotman, S. M. Opal, J. P. Pribble, R. C. Bone, G. Emmanuel, D. Ng, D. C. Bloedow, M. A. Catalano; IL-1RA Sepsis Syndrome Study Group. 1994. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit. Care Med. 22: 12-21.
23. Opal, S. M., C. J. Fisher, Jr., J. F. Dhainaut, J. L. Vincent, R. Brase, S. F. Lowry, J. C. Sadoff, G. J. Slotman, H. Levy, R. A. Balk, et al. 1997. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit. Care Med. 25: 1115-1124.
24. Gabay, C., M. F. Smith, D. Eidlen, and W. P. Arend. 1997. Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein. J. Clin. Invest. 99: 2930-2940.
25. Bargetzi, M. J., M. Lantz, C. G. Smith, F. M. Torti, I. Olsson, S. P. Eisenberg, and H. F. Starnes, Jr. 1993. Interleukin-1 beta induces interleukin-1 receptor antagonist and tumor necrosis factor binding protein in humans. Cancer Res. 53: 4010-4013.
26. Gabay, C., J. Gigley, J. Sipe, W. P. Arend, and G. Fantuzzi. 2001. Production of IL-1 receptor antagonist by hepatocytes is regulated as an acute-phase protein in vivo. Eur. J. Immunol. 31: 490-499.
27. Lamacchia, C., G. Palmer, C. A. Seemayer, D. Talabot-Ayer, and C. Gabay. 2010. Enhanced Th1 and Th17 responses and arthritis severity in mice with a deficiency of myeloid cell-specific interleukin-1 receptor antagonist. Arthritis Rheum. 62: 452-462.
28. Malyak, M., M. F. Smith, Jr., A. A. Abel, and W. P. Arend. 1994. Peripheral blood neutrophil production of interleukin-1 receptor antagonist and interleukin-1 beta. J. Clin. Immunol. 14: 20-30.
29. Lamacchia, C., G. Palmer, and C. Gabay. 2007. Discrimination of C57BL/6J Rj and 129S2/SvPasCrl inbred mouse strains by use of simple sequence length polymorphisms. J. Am. Assoc. Lab. Anim. Sci. 46: 21-24.
30. Postic, C., M. Shiota, K. D. Niswender, T. L. Jetton, Y. Chen, J. M. Moates, K. D. Shelton, J. Lindner, A. D. Cherrington, and M. A. Magnuson. 1999. Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. J. Biol. Chem. 274: 305-315.
31. Clausen, B. E., C. Burkhardt, W. Reith, R. Renkawitz, and I. Förster. 1999. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 8: 265-277.
32. Arend, W. P., M. Malyak, C. J. Guthridge, and C. Gabay. 1998. Interleukin-1 receptor antagonist: role in biology. Annu. Rev. Immunol. 16: 27-55.
33. Gabay, C., B. Porter, G. Fantuzzi, and W. P. Arend. 1997. Mouse IL-1 receptor antagonist isoforms: complementary DNA cloning and protein expression of intracellular isoform and tissue distribution of secreted and intracellular IL-1 receptor antagonist in vivo. J. Immunol. 159: 5905-5913.
34. Bigler, C. F., D. A. Norris, W. L. Weston, and W. P. Arend. 1992. Interleukin-1 receptor antagonist production by human keratinocytes. J. Invest. Dermatol. 98: 38-44.
35. Arend, W. P. 2002. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev. 13: 323-340.
36. Horai, R., M. Asano, K. Sudo, H. Kanuka, M. Suzuki, M. Nishihara, M. Takahashi, and Y. Iwakura. 1998. Production of mice deficient in genes for interleukin (IL)-1alpha, IL-1beta, IL-1alpha/beta, and IL-1 receptor antagonist shows that IL-1beta is crucial in turpentine-induced fever development and glucocorticoid secretion. J. Exp. Med. 187: 1463-1475.
37. Matsuki, T., R. Horai, K. Sudo, and Y. Iwakura. 2003. IL-1 plays an important role in lipid metabolism by regulating insulin levels under physiological conditions. J. Exp. Med. 198: 877-888.
38. Heinrich, P. C., J. V. Castell, and T. Andus. 1990. Interleukin-6 and the acute phase response. Biochem. J. 265: 621-636.
39. Moshage, H. 1997. Cytokines and the hepatic acute phase response. J. Pathol. 181: 257-266.
40. Billiar, T. R., R. D. Curran, D. L. Williams, and P. H. Kispert. 1992. Liver nonparenchymal cells are stimulated to provide interleukin 6 for induction of the hepatic acute-phase response in endotoxemia but not in remote localized inflammation. Arch. Surg. 127: 31-36, discussion 36-37.